Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi ANESRI, Mike & PhilB and everyone.
Thanks for the notes. Thanks also to you ANESRI for your long service. Great that you are still around.
And, yes, with increased market attention on AEMD, in the future, it seemed like a good idea to not leave the moderator role vacant for too much longer. In case some are wondering about me, I first invested in AEMD in Jan. 2008 at around 0.65/share. But I soon sold all my holdings in the low .60s. But by late 2008 I got back in in the low .30s, and have held and purchased more during the decline since then. I trade in and out a small portion of my holdings. It was sometime in 2009 that I first started to be on this IHub board. I haven't posted a lot, but did when I could.
I first invested in stocks in the 1980s. I worked in computing for 25 years, but left in 2002 after 10 years as a Director of MIS managing a staff of 45. I have no background in medicine or medical devices.
I’ve participated in Yahoo Boards, and previously some private investment groups. I’ve seen enough on Yahoo Boards to know how some good groups can deteriorate and/or get swamped with spammers and deceptive people. I’ve come to greatly appreciate the intelligent, respectful and the knowledgeable well researched contributions on this board. And, as I stated, my intention in assuming the moderator role is to do what I can to help keep this constructive, civil and on-topic.
I’ll welcome any help or advice, public or private, anytime.
BBarry.
I have become Board Moderator. My primary intention is to hold the position to avoid any spammer or disruptive person from becoming moderator. Beyond that my administrative contributions may be limited due to my time constraints. I will be ready to step aside whenever some responsible & civil person volunteers to take on the role. Or, having some “assistant moderators” is also an option.
BBarry.
@3:33PM today, Fidelity posted AEMD's 8-K filing (the sec filing made this morning), which contains todays PR.
Fidelity is not yet showing today's PR. I don't see today's news on the Fidelity ActiveTrader news link for AEMD. The same absence of this news when I log into fidelity.com as web-browser user.
This news does show on E*Trade and Yahoo.
Prior to this, I've always quickly seen AEMD news in the Fidelty ActiveTrader system.
re clinical partners, I was looking to see if todays news would state the same partners named in the Jan 3 PR release, which stated that the work would "be conducted by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC.".
Here's to hoping that JJ is planning a separate PR, very soon, to highlight these named partners & the "principle investigator".
interesting that the 640K bid @.095 from late Friday, seems to have remained through to today's trading. Might be worth watching to see if this bid, which is currently accumulating at .095 remains patiently at .095 thru next day OR if this buyer demonstrates any urgency to their desire to purchase $60,000+ worth of shares.
Many of today’s complaints are painfully valid. However, how can you say we’re hearing “nothing” on HepC???
On April 16th we heard that the IDE was resubmitted to FDA on March 25. In that same paragraph we have the reference to the undetectable HCV results. [I agree there should be more data out by now] but this is not “nothing”, especially if it remains true that FDA will respond to the 3/25 resubmissions within 30 days!!!?
That should mean that rather than being another disappearing act, we will get an announcement soon re the start of the first US Clinical trials on "10 end stage renal disease patients infected with HCV and be conducted by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC."
I agree that the lack of add'l data out of the Medanta HCV studies is very frustraiting. But, unfortunately this is consistent with most efforts within India to build, construct, or innovate. The Medanta Medicity delays within India are an area that JJ has limited control over, at best.
Funding & even more important will be the implied endorsement-by-association with :
the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC.
which would come soon after the recently announced subcontract relationship with the well-respected Battelle ...
which as we know is a follow-up to the previous multi-year DARPA contract
We are finally seeing some momentum building, that includes revenue generation, AND partnerships with respected organizations that are named, as opposed to the vague "thought leaders' moniker.
Resources to help fund the 10 patient trial could come from the sources identified in the Jan 3 PR which stated:
"The proposed trial, which we expect would begin shortly following an approval by FDA of the IDE, would enroll 10 end stage renal disease patients infected with HCV and be conducted by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC."
8K this AM, subcontract with Battelle for DARPA DLT integration work
ENTRY INTO MATERIAL DEFINITIVE AGREEMENT
On April 11, 2013, Aethlon Medical, Inc. (the "Company") entered into a subcontract agreement (“Subcontract”) with Battelle Memorial Institute (“Battelle”). The Subcontract provides for the Company to provide services under Prime Contract No. HR0011-13-C-0023 (“Prime Contract”), which was awarded to Battelle by the Defense Advanced Research Projects Agency (DARPA) on March 12, 2013. The amount of the prime contract award is $22,830,840. The objective of the Prime Contract is to integrate component technologies developed in a previously established DARPA program entitled Dialysis Like Therapeutics (DLT). The DLT integration program will design, test, and validate an extracorporeal blood purification system to treat sepsis. The program endpoint is the submission of an Investigational Device Exemption (IDE) to the United States Food and Drug Administration.
The Subcontract award from Battelle is a cost-plus contract over the course of approximately four years. Payments to the Company will be dependent upon the time and costs incurred on the Subcontract under the direction of Battelle. The Subcontract is composed of a base period and three option periods to achieve a number of tasks to integrate the DLT component technologies. The right to grant those option periods is also at the discretion of the prime contractor. There can be no assurance that the Company alone, or with third party participants, will achieve the identified tasks under the Subcontract to the satisfaction of Battelle and the government. The Company began work on the Subcontract effective April 1, 2013.
The Company was previously awarded a DLT contract by DARPA to develop two technology components that will be tested in the systems integration program for use within an extracorporeal device to treat sepsis. The first component is a selective therapeutic filtration mechanism to eliminate sepsis precursors, bacterial toxins, viral pathogens, and disease enhancing exosomes from the entire circulatory system. The second component is a blood processing system with an open architecture to deliver a variety of extracorporeal therapies without the need for systemic anticoagulant administration. To date, the Company has achieved eleven milestone goals under this contract and is in year two of that five year contract.
Is some of this recent despair an over-reaction? Over-reactions are easy especially when many have been painfully patient for quite a few years. I share the frustrations that many have expressed. Perhaps it is due to the years of waiting, but it seems that over-reactions are a recurring theme here, whether it is premature talk of going to Vegas each time we see a surge up, or some of the recent angst.
This week’s challenge might be to avoid the slow decline on low volume … But, I’m still buying when I can, as I’ve done the past several days.
Thanks to the many helpful contributors on this board.
BBarry
Thanks Truthteller. For another perspective: A WSJ editorial on Feb 27, goes into details explaining ways that the President currently has full legal authority to require that department managers use their own discretion to select and prioritize expense categories that can be cut to comply with the dollar savings required by the sequester. Apparently this is possible due to loopholes in the “sloppy law” that the 11th hour sequester legislation included. But it would appear that the minutia of these available policy options are not as interesting to 1.) politicians wanting to score political points by trying to bash opponents; nor to 2.) the media coverage of threats to jobs and programs. Threats that are very real in the current politicized climate in Washington.
My intention is to not get into a political debate.
In terms of near-term potential for AEMD re federal Government funds, I do find legitimate hope in the fact that DARPA is still announcing new contracts, as recently as the past few days. .
BBarry
total fed budget this year is $3.553 Trillion, after sequester cuts. Compared to last fiscal year when total fed budget was $3.538 Trillion. So this FY the total Fed spending is scheduled to be $15 Billion more than last year.
Including the Sequester cuts, this years total Fed budget will be 30% higher than it was in 2007.
Total US Government spending will be higher this Fiscal Year than last Fiscal Year, even with these small sequester cuts amounting to about 2.2% of the total federal budget. As the drama of politicized instilling of fear re these cuts is replaced (hopefully) by some responsible leadership and management... we should be seeing less of the "severe" articles.
Meanwhile, for example, DARPA is still spending lots of money. If you do a news search on "darpa awards" or "darpa contracts" you can see that DARPA is still announcing new 7 or 8 figure awards, as recently as yesterday.
Encouraging note from JJ. He knew the 30 day timeframe had raised expectations re IDE submission to FDA. On that topic, his note is positive that we are still moving toward the FDA approved study of HCV patients to be done by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC.
and the new $25M DARPA systems integration contract in partnership with two larger companies remains on the horizon.
Meanwhile Aethlon has earn $2M in revenuse from DARPA re the sepsis project.
I think this note to shareholders reinforces our expectations that February 2013 will bring substantive positive news.
JJ's Brian Britt interview was on Jan 3, 2013. The date is listed on the Brian Britt webpage where the podcast links are available. Also, during the interview, JJ states (to paraphrase) today we submitted the IDE to FDA...
Soooooo.... although in the same interview JJ stated that they expected FDA's response within 30 to 60 days, several posters on this board & the Yahoo board have stated with confidence that Aethlon will get a response within 30 days. My guess is that JJ's statement about 30 to 60 days was due to his trying to be conservative on the timing, since he has been burned by his date predictions
re the "New York City-based Exosome Diagnostics" mentioned in this interesting artcle...
the Chief Science Officer of Exosome Diagnostics is Wayne D. Comper, PhD, DSc http://www.exosomedx.com/people/management.html
Wayne Comper is also a member of Aethlon's Exosome Sciences Advisory Board, as announced in the December 2009 PR titled "Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board" which stated that "Dr. Comper is one of the founders, Director and Chief Science Officer of Exosome Diagnostics, Inc. " that 2009 PR is at http://www.bizjournals.com/prnewswire/press_releases/2009/12/15/LA26089
Interesting article, Truthteller.
I don't always try to research these connections, but this one looks intriguing!
Fidelity now is allowing buys of AEMD. I just checked in my Fidelity AT account. This morning I had seen that they were not allowing buys, but they seem to have changed that control sometime in the past couple hours.
BBarry
Thanks Bryan, Aethlon as a subcontractor seems likely given their current size and resources. If that is how this plays out, three things that will be interesting to see are: 1.) the jump in visibility of AEMD when it is included in a PR sent out by one of these larger partners; 2.) how well did JJ do in negotiating for a fair portion of the contract revenues?; and 3.) to what extent Aethlon has protected it's future licensing and shared revenue.
BBarry
Thanks Lee. I also find it encouraging that JJ included reference to this potential contract in his recent presentation. That reference continues on the theme that was included in Aethlon's August 21 PR where they stated
"The Company also disclosed that it has teamed with two larger organizations in response to a follow-on DLT contract opportunity entitled DARPA BAA-12-36. The announcement of DARPA BAA-12-36 contract awards is anticipated later this fall."
regarding partnering with "two larger organizations", that does mean that JJ will need to coordinate any announcements, hence this time he would not be free to release partial news, as he was prior to the full news of the first DARPA contract coming out. It also means that any final round of contract negotiations would involve more than just Aethlon.
BBarry
As we approach Oct 23rd, which is the date that DARPA stated they would announce the new contract, how confident can we be that DARPA will make this date?
Didn't that 10/3/11 news of Aethlon's first DARPA contract come days or a week+ after we were all led to expect it?
Certainly DARPA's recent commitment to year 2 of the first AEMD-DARPA contract raises our expectations.
Thanks for the recent helpful posts.
BBarry
Keep in mind, Lee, that today’s total volume was worth only roughly $47,000. Yes, it was double recent ave volume, but given the many short term traders and the low price, this could be just the kind of volatility we’ve often seen. Not pleasant to see the closing price, but I’d guess that if a few people had valid major news, good or bad, the volume would be much higher.
BBarry
New YouTube interview with Aethlon CEO JJ. the video is titled "This Week in Med IT Sept. 4, 2012 - Aethlon Medical"
here is link to DARPA AEMD $6.8M Contract news http://www.aethlonmedical.com/products/darpa-sepsis-program.htm
CADC Halted, Privatization offer @ $2.65 Per Share Cash
09:15 AM EDT, 07/26/2011 (MidnightTrader) -- China Advanced Construction Materials (CADC:$2.30,00$0.28,0013.86%) is halted. The company says its Board of Directors has received a preliminary, non-binding offer from its Chairman and Chief Executive Officer, Xianfu Han and Weili He, Vice Chairman and Chief Operating Officer, to acquire the company for $2.65 per share in cash.
NUIN volume & price showing strength today ...no new news out yet(?)
a breakout on very high volume, during last 3 days.
I'm not a chartist, but I believe the 3 month chart of NTWK looks like a classic "cup with handle" breakout.
Surge in volume early this afternoon, pushing price up 5.8% so far, on twice ave volume of past 10 days.
Pre-market 30,000 shares traded this morning. ???
Well above recent average volume.
8-K out this morning. Results of FY ended June 30
brief but positive!
NetSol Technologies Ltd. (NetSol PK)– FISCAL YEAR ENDED JUNE 30, 2010
FINANCIAL HIGHLIGHTS
· Revenues increased by 71% over the corresponding year of 2009
· Gross profit margins increased to 71% of revenues over the FY ended June 30, 2010 compared to 42% in the corresponding year
· Company posted net income of Rs. 952 million for the FY ended June 30, 2010 in comparison of Rs. 294 million in corresponding year ended June 30, 2009
NetSol PK posted revenues of Rs. 1.845 billion which represents an increase of 71% as compared to Rs. 1.081 billion reported last year. Gross profit in the year under review jumped to Rs. 1.315 billion as compared to Rs. 453 million reported in the corresponding year. During the current financial year ended June 30, 2010, the company posted net income of Rs. 952 million compared to Rs. 294 million in the year ago period. Earnings per share remained at Rs. 12.38 compared to an EPS of Rs. 4.12 reported in the corresponding year.
Powerful buying today. Up almost 10% on about 7X ave volume. Impressive to see as we approach the Sept 8th report and CC.
presumably today's action will spark some new interest.
about 51,000 shares traded just after 2PM ET time. at HOD on volume of those few trades.
NEWS: Earnings Released this morning
Sino Agro Food, Inc. Announces First Half Results for 2010 and Schedules Shareholder Conference Call
08/12 09:00 AM
GUANGZHOU, China--(BUSINESS WIRE)-- Sino Agro Food, Inc. (SIAF:$0.6000,$0.0000,0.00%) , an emerging integrated, diversified agriculture technology and organic food company with subsidiaries operating in China, is pleased to announce operating results for second quarter 2010 and sets date for shareholder conference call to discuss current operations and provide updated guidance.
Results of Operations
Assets. Our total assets were $85,451,738 as of June 30, 2010, an increase of 9% when compared to $78,148,919 as of June 30, 2009. This increase of assets from June 30, 2009 to June 30, 2010 was primarily a result of the growth in net earnings and injection of additional capital.
Liabilities. Our total liabilities were $6,834,442 at June 30, 2010, a decrease of 50% when compared to $13,585,410 as of June 30, 2009. This decrease was primarily due to improvements in the Company’s cash flows during the periods reported.
Total Stockholders’ Equity. Our stockholders’ equity was $78,617,296, or $1.51 per share as of June 30, 2010, representing an increase of 22% compared to $64,544,922 as of June 30, 2009. This increase in equity was primarily due to increases in net earnings, additional capital injected, exchange translational gains and minority interest, but there was no increase of common stock issued and outstanding.
Revenues. Our Revenue was $13,170,210 for the 6 months ended June 30, 2010, representing an increase of 64% from $8,016,158 for the same period ended June 30, 2009. The increase was primarily due to an audited adjustment made to 2009’s revenue being carried to this quarter, and there was an increase of sales revenue in the dairy due to the quarter’s heavy launching of sales of retail dairy products.
Gross Profits. For the three months ended June 30, 2010, we had gross profit of $5,100,003, an increase of 148% when compared to a gross profit of $2,053,131 for the three months ended June 30, 2009. This increase was due to higher productivities, sales margins, increased operational efficiency and increased profits derived from the sale of retail dairy products. Further reductions were made by a larger number of crops being grown and harvested internally instead of outsourcing raw materials from third parties. Dairy productions also increased as the maturity of our cows have begun reaching better yields. At the same time there was better performance from Capital Award Inc. having obtained a service contract to build its first Aquaculture Fish Farm in China. During this same period, there was adjustment of sales from 2009 being adjusted to this quarter as requested by our auditor due to result of their audit done for our fiscal year ended December 2009 that increased revenue for this quarter.
Our net income from operation was $1,765,449 or $0.03 per share and $949,088 net of minority for the three months ended June 30, 2010 and 2009, respectively. This represents an 86% increase from 2009 to 2010 during the same period. The increase was due to an increased profit margin during the three months ended June 30, 2010 compared to the three months ended June 30, 2009.
Interest expense was $237,925 and $118,349 for the three months ended June 30, 2010 and 2009, respectively, an increase of $119,576. The increase is due to an increase in debt servicing during the quarter of 2010 compares to same quarter of 2009.
The Company will publish its full first half year report on OTCmarkets.com for review by August 15th, 2010. The format presented is the result of current changes to the fiscal year ending to June 30th in preparation of its Form 10 filing with the SEC. Comparatives will vary based on this. Quarterly break down will be provided in the report to be filed with OTCmarkets.com.
The Company will host a shareholder conference call on August 31st, 2010 at 11:00 AM EST to discuss both second quarter earnings as well as guidance for the remainder of the year. Shareholders will be provided with a question and answer session. Details on how to attend the conference call will be provided on or before August 27th, 2010. Shareholders are reminded that August 27th, 2010 is also the Ex. Dividend Date in order to receive the previously announced annual cash dividend.
The Company is currently waiting on final audited reports for the periods ending December 31st 2008 and 2009 to be finalized and issued by our auditor anticipating sometimes within the month of August 2010 and subsequently with the auditor’s review for fiscal year ended June 30, 2010 within the month of September 2010. The Company expects to have the completed audited reports’ results published prior to the shareholder conference call. However the financial results presented hereof have included all adjustments made by our auditors for fiscal years ended December 31, 2008 and 2009.
The Company Investor Relations team will be in China from August 14th through the 21st visiting all operations and the site construction for its new aquaculture demonstration farm. During the visit all operations will be documented and recorded so that a video presentation and Company documentary can be produced and provided to shareholders on DVD by request or can be viewed via the Company web site.
Joe’s couple month’s history of persistent rants, in his accusations against Chad and SIAF’s management , will certainly provide substantive materials to that SIAF’s lawyers will use against Joe. The frequency and some of the tone and content, will be used to raise questions regarding Joe’s emotions, motives, and/or personal vendetta.
Thanks to all who shared their research and insights on this.
Joe, I suspect you will disagree with me on this, but sometimes it takes a greater honor and strength of integrity to walk away from a fight. Especially if in fighting for their sense of honoring higher principles, the fight continues to damage other shareholders investment.
NetSol founders buy over 1M shares NTWK
Press Release Source: NetSol Technologies, Inc. On Tuesday May 18, 2010, 8:00 am
CALABASAS, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- NetSol Technologies, Inc. ("NetSol") (Nasdaq:NTWK - News) (Nasdaq Dubai:NTWK), a U.S. corporation providing global business services and enterprise application solutions to private and public sector organizations worldwide, announced today that the Company's three founding officers acquired over 1 million shares of NetSol stock through a private transaction. The shares were purchased at the price of $0.87 on May 14, 2010. Najeeb Ghauri, CEO and Chairman, acquired 375,000 shares of stock. Salim Ghauri, President APAC, acquired 350,000 shares. Naeem Ghauri, President NTE, acquired 309,383 shares. Each founder filed an SEC Form 4 to report the acquisition.
Accumulation shown in chart, below, is quite interesting. So, So many days, we've seen share price erosion even on days with plenty of larger block buys pushed the intra-day price up, only to drop on smaller volume later in the day. Chart below confirms that accumulation continues.
BBarry
http://stockcharts.com/h-sc/ui?s=AEMD&p=D&b=5&g=0&id=p83301009818
Can you provide an as of date? on your last post? or better yet, a Link. Thanks.
signs of some volume buying since mid-morning today. Here's to hoping we see the start of a new trend here.
yes, I noticed that statement, re a new way to re-establish a patent control on an expiring drug patent. This was the first time I heard that. I thought it was significant, that JJ took the extra half minute or so, to emphasize this point, within the limited 25 minutes or so that he had.
Seems like a whole new way to lock-in a partnership with a drug company on a defined treatment protocol... ? or at least a new way, in terms of potential partnerships with Aethlon.
Although a few more cents gain would have been nice, I'd much rather see a slow steady climb, in the coming weeks and months, rather than the gap up kind of jump, like we had in late October 09, that is most often not sustainable.
Could be fine if one is a fast moving trader... but with some of the large quantities of shares that some of us have, it can be harder to sell large lots to try to lock in a nickel or so single day gain... even on a day with 1M shares traded.
It would also be great to see us have a significant net gain on the week, on very high volume. we shall see.
Very encouraging news out of yesterday presentation!
BBarry